RIGL Rigel Pharmaceuticals, Inc., featured news, full reports, and detailed RIGL.O charts.
Rigel Pharmaceuticals, Inc. (RIGL) Wrap Up:
Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and is based in South San Francisco. Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to file one new investigative new drug, or IND, application in a significant indication each year. We have achieved this goal each year beginning in 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Our productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and thrombocytopenia, and cancer, as well as partnered product development programs relating to asthma and cancer. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f07%2f0001047469-08-002350.html#FIS_BUSINESS"
Rigel Pharmaceuticals, Inc. (RIGL:NASDAQ)
Snapshot of Rigel Pharmaceuticals, Inc. (RIGL)
|
OPEN
$7.19
|
PREVIOUS CLOSE
$7.26
|
|
|
DAY HIGH
$7.56
|
DAY LOW
$7.17
|
|
|
52 WEEK HIGH
07/21/09 - $14.75
|
52 WEEK LOW
03/6/09 - $4.19
|
|
|
MARKET CAP
383.5M
|
AVERAGE VOLUME 3 mo
932.1K
|
|
|
DILUTED EPS TTM
$-3.24
|
SHARES OUTSTANDING
51.8M
|
|
|
RIGL Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Telaprevir is a potential blockbuster drug for treating hepatitis C, with a multibillion-dollar market. Vertex could get FDA approval for it next year
Investors Thursday weighed reports showing a jump in the Philadelphia Fed index, a decline in jobless claims, and a rise in housing starts
related news
RIGL Details
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. The companys products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono. The company was founded in 1996 and is based in South San Francisco, California.
RIGL Top Compensated Officers
Executives, Board Directors
Key developments for Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals Inc. reported unaudited financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, the company reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Loss from operations was $26.7 million against $38.7 million a year ago. Loss before income taxes was $26.7 million against $37.7 million a year ago. For the nine months ended September 30, 2009, the company reported a net loss of $86.5 million, or $2.32 per share, compared to a net loss of $99.0 million in the first nine months of 2008, or $2.76 per share. Loss from operations was $86.9 million against $102.7 million a year ago. Loss before income taxes was $86.6 million against $98.98 million a year ago.
Rigel Pharmaceuticals, Inc. - Conference Presentation Calls
Rigel Pharmaceuticals, Inc. - Conference Presentation Calls
RIGL Competitors
| Company | Last | Change |
| Arena Pharmaceuticals Inc | $3.49 USD | -0.03 |
| Idenix Pharmaceuticals Inc | $1.92 USD | -0.04 |
| MVIR BTA B, Medivir AB | kr68.00 SEK | 0.00 |
| Pharmasset Inc | $21.10 USD | +1.30 |
| Evotec Aktiengesellschaft | $6.63 USD | +0.13 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | RIGL | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 2.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
RIGL |
||
RIGL transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Rigel Pharmaceuticals, Inc.
-
Fundamental and Technical Research for LINE, PCAR, RIGL, INTC, NTAP and HERO Posted on BenchmarkJournal.com Today
Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to...
Market Wire, 11/02/09 · More from publication